# Development of a Series of Tanshinone Derivatives Through Scaffold Hopping for Treating Non-Small-Cell Lung Cancer (NSCLC)

**Authors:** Lan-Xin Zhou, Zheng-Yu Shu, Heng Li, Hui Zhong, Dou-Nan Xu, Lei Tang, Chu-Jiao Hu, Cheng Luo, Huan Xiong

PMC · DOI: 10.3390/molecules31030446 · Molecules · 2026-01-27

## TL;DR

Researchers developed new tanshinone derivatives that show strong anti-cancer activity against non-small-cell lung cancer cells.

## Contribution

A novel scaffold-hopping strategy was used to design tanshinone derivatives with enhanced anti-NSCLC activity.

## Key findings

- Compounds S2-4 and S2-8 showed the highest potency against H838 NSCLC cells.
- Molecular docking and SAR analysis identified key structural features for improved activity.
- Several compounds exhibited superior or comparable cytotoxicity compared to β-lapachone.

## Abstract

Non-small-cell lung cancer (NSCLC) is one of the most prevalent cancer types and accounts for the majority of cancer-related deaths worldwide. Tanshinone and its derivatives exhibit diverse biological activities, and their prominent antitumor potential has been well documented. In this study, we rationally designed a series of tanshinone derivatives with a scaffold-hopping strategy. Thirty-five tanshinone derivatives were synthesized, and their cytotoxic activities against the NSCLC cell lines A549 and H838 were investigated. Concurrently, their safety profile was assessed in BEAS-2B cells. The results showed that compounds S2-1, S2-4, and S2-8 exhibited superior inhibitory activity against A549 cells compared with the positive control, β-lapachone. Meanwhile, compounds S2-1, S2-3, S2-4, S2-8, S2-13, and S2-14 exhibited similar or increased antiproliferation activity against H838 cells. Compounds S2-4 (0.58 ± 0.07 μM) and S2-8 (0.42 ± 0.04 μM) demonstrated the greatest potency towards H838 cells; compounds S2-13 (1.28 ± 0.13 μM) and S2-14 (1.80 ± 0.24 μM) exhibited potent and selective activity towards H838 cells. Molecular docking studies of S2-4/NLRP3 and S2-14/STAT3, combined with the structure–activity relationship (SAR) analysis, indicated that the benzofuran core containing an ortho-quinone, along with an amide linkage and a 1,2,3-triazole group introduced at the C-2 position of the furan ring, is an effective chemical scaffold for enhancing the anti-NSCLC activity of tanshinone derivatives.

## Linked entities

- **Proteins:** NLRP3 (NLR family pyrin domain containing 3), STAT3 (signal transducer and activator of transcription 3)
- **Chemicals:** Tanshinone (PubChem CID 114917), β-lapachone (PubChem CID 3885), S2-1 (PubChem CID 11065204), S2-4 (PubChem CID 24798725), S2-8 (PubChem CID 37419)
- **Diseases:** Non-small-cell lung cancer (MONDO:0005233), NSCLC (MONDO:0005233)

## Full-text entities

- **Genes:** NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}
- **Diseases:** cancer (MESH:D009369), NSCLC (MESH:D002289)
- **Chemicals:** S2-13 (-), furan (MESH:C039281), benzofuran (MESH:C105430), beta-lapachone (MESH:C014638), quinone (MESH:C004532), Tanshinone (MESH:C021751)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12900021/full.md

## Figures

45 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12900021/full.md

## References

25 references — full list in the complete paper: https://tomesphere.com/paper/PMC12900021/full.md

---
Source: https://tomesphere.com/paper/PMC12900021